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The cumulative follow-up period was 251,538 catheter 
days, and the median duration of UACVP indwelling was 
439.0 days (1–2, 24). There was no UACVP-related mor-
tality throughout the study period. A total of 83 UACVP-
related complications occurred (19.2 %), including 43 
cases of infection (9.9 %, 0.17/1000 catheter days), ten 
cases of catheter-related thrombosis (2.3 %, 0.040/1000 
catheter days), ten cases of occlusion (2.3 %, 0.040/1000 
catheter days), nine cases of catheter dislocation (2.0 %, 
0.036/1000 catheter days), five cases of port leakage 
(1.2 %, 0.019/1000 catheter days), four cases of skin dehis-
cence (0.9 %, 0.015/1000 catheter days) and two cases of 
port chamber twist (0.5 %, 0.008/1000 catheter days). The 
removal-free one-year port availability was estimated at 
87.8 %.
Conclusions UACVPs were of long-term utility, with 
complication rates comparable to those of chest CVPs pre-
viously reported.
Keywords Upper arm central venous ports · Long-term 
availability · CVP-related complications
Introduction
Central venous ports (CVPs) are good medical devices 
to facilitate the long-term administration of intravenous 
chemotherapy (CTx) or fluid supplementation. Since 
continuous systemic chemotherapy such as FOLFOX or 
FOLFIRI in combination with molecular-targeted drugs 
has been regarded as the standard treatment for advanced 
colorectal cancers [1–3], the subcutaneous implantation of 
CVPs has become an essential device in daily medical care. 
Moreover, since the combination regimen of 5-fluorouracil, 
folinic acid, oxaliplatin and irinotecan (FOLFIRINOX) has 
Abstract 
Background We have employed upper arm central venous 
ports (UACVPs) since 2006 for long-term intravenous 
chemotherapy (CTx) or fluid supplementation. We evalu-
ated the long-term availability of CVPs implanted in the 
upper arm to determine whether UACVPs could be one of 
the treatment options besides chest CVPs in terms of CVP-
related complications.
Methods We reviewed the medical records of all patients 
who underwent subcutaneous implantation of UACVPs at 
Kyoto University Hospital from 1 April, 2006 to 30 June, 
2009. We assessed the indwelling duration of the UACVPs 
and the incidences of early and late UACVP-related 
complications.
Results A total of 433 patients underwent subcutane-
ous implantation of UACVPs during this time period. 
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been proposed as a new standard of care for metastatic pan-
creatic cancer patients [4], the subcutaneous implantation 
of CVPs has been performed more frequently than ever 
before.
The most common site for the implantation of CVPs 
is the anterior chest via the subclavian vein (chest CVPs). 
However, the insertion of CVPs into the subclavian vein is 
sometimes complicated by pneumothorax, pneumohemo-
thorax, or arterial punctures [5–8]. In addition, the long-
term usage of chest CVPs is sometimes complicated with 
pinch-off syndrome, a severe complication in which the 
catheter becomes kinked, compressed or even fragmented 
at the narrow space between the clavicle and the first rib 
due to repetitive arm motion [9–11]. The implantation of 
CVPs via the internal jugular vein is considered to be safer 
compared to access via the subclavian vein [12–14]. In 
contrast, some authors prefer to implant CVPs in the upper 
arm or forearm via the basilic or axillary veins because of 
safer puncture procedures, and concluded that arm CVPs 
could be suitable for long-term usage with minimal com-
plications [15–17]. Therefore, we chose to employ upper 
arm CVPs (UACVPs) rather than chest CVPs to prevent 
the possible complications associated with chest CVPs [18] 
and hypothesized that UACVPs could be one of the feasible 
options for CVPs, especially for systemic chemotherapy. In 
order to re-evaluate the utility of UACVPs, we examined 
UACVP-associated complications and long-term utility of 
UACVPs in a larger cohort of our patients.
Patients and methods
We reviewed the medical records of all patients who 
underwent subcutaneous implantation of UACVPs at 
Kyoto University Hospital from 1 April, 2006 to 30 
June, 2009. UACVPs were implanted in 433 consecutive 
patients for the long-term administration of chemother-
apy or fluid supplementation during this period, accord-
ing to the implantation techniques described previously 
[18]. Almost all the patients (427, 98.6 %) suffered from 
malignant diseases including colon cancer (235, 54.3 %), 
gastric cancer (45, 10.4 %), breast cancer (45, 10.4 %), 
lung cancer (29, 6.7 %), pancreatic cancer (19, 4.4 %), 
esophageal cancer (18, 4.2 %) and other malignancies 
(36, 8.3 %). The majority of these patients (386, 89.1 %) 
required the implantation of UACVPs for systemic CTx 
(CTx group). For the remaining 47 patients, the UACVPs 
were implanted for fluid supplementation, or because of 
inaccessibility to the peripheral blood vessels (non-CTx 
group). Furthermore, 38 patients from the non-CTx group 
were at the end stage of their malignancies, and required 
best supportive care. We performed routine computed 
tomography scanning every 3 or 4 months in all patients 
from the CTx group to assess the effectiveness of the treat-
ment, and to detect UACVP-related complications includ-
ing venous thrombosis. Using the same implantation pro-
tocol guided by ultrasonography (US) [18], all procedures 
were performed by senior surgeons under local anesthe-
sia in a day surgery unit equipped with a mobile X-ray 
fluoroscopic scanner and US device. The UACVPs were 
implanted in the patient’s non-dominant upper arm, with 
the exception of breast cancer patients with axillary lymph 
node dissection, who underwent UACVP implantation in 
the unaffected upper arm. In 2006, we employed a Slim-
Port® system (Bard Access Systems, Salt Lake City, UT, 
USA), but later decided to employ a Titanium Vital Port® 
system (Cook Vascular, Leechburg, PA, USA)(Fig. 1a) 
since the latter port is smaller and seems to be more suit-
able for subcutaneous implantation in the upper arm. We 
followed the patients with implanted UACVPs until March 
2014. Follow-up was discontinued upon removal of the 
UACVPs, at the patient’s death, or at the end of the study 
period. The information was retrieved from the medi-
cal charts, and the data included UACVP-related infec-
tions, i.e., catheter infection and port pocket infection 
(Fig. 1d)], skin dehiscence (Fig. 1e), venous thrombosis 
(Fig. 1f–h), catheter dislocation (Fig. 1i, j) or occlusion, 
port chamber twist, port leakage, catheter fracture and 
needle dislodgement. Catheter infection was defined by 
the following conditions—(1) when blood culture tests 
were positive for microorganisms including a coagulase-
negative staphylococcus (a typical pathogen associated 
with long-term indwelling of venous catheters), or (2) 
when blood culture tests were negative but a high fever 
persisted without any possible infection foci other than the 
CVPs. Port pocket infection was defined as an erythematic 
or painful induration, or tenderness at the port site often 
complicated with pus retention. Venous thrombosis was 
confirmed by enhanced computed tomography, magnetic 
resonance imaging or US. Catheter occlusion was defined 
as the failure to aspirate and flush the contents via CVPs. 
In this study, aspiration occlusion, where the blood can-
not be aspirated but the port/catheter system can be flushed 
without resistance, was not regarded as catheter occlu-
sion, since aspiration occlusion can be episodic and nor-
mal catheter function can recover spontaneously without 
Fig. 1  Subcutaneously implanted UACVP and representative mani-
festations of UACVP-related complications. a Titanium Vital Port 
system. b, c CVP was implanted on the ulnar side in the upper arm. d 
Port pocket infection with erythematic induration. e Skin dehiscence 
leading to the exposure of a subcutaneous CVP. f Venous thrombosis 
resulting in swelling of the left upper extremity. The patient under-
went systemic anticoagulant therapy via the right peripheral blood 
vessel. g Bilateral pulmonary embolism. h Thrombus detected around 
the catheter in the subclavian vein. i, j Catheter dislocation on three-
dimensional computed tomography
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any intervention [18]. The study was conducted in accord-
ance with the Helsinki Declaration, and the protocol was 
approved by the Ethics Committee of Kyoto University 
Hospital (Approval No. E-845).
Statistical analysis
The time to the development of UACVP-related compli-
cations and to port removal, i.e., complication-free and 
overall (removal-free) port availability, respectively was 
evaluated using the Kaplan−Meier product limit method. 
Patient death and port removal without any UACVP-asso-
ciated complications, including scheduled removal at the 
cessation of chemotherapy, were analyzed as censored 
cases. Differences in UACVP-related complication rates by 
the addition of bevacizumab (Bmab) were evaluated using 
Fisher’s exact test. Statistical significance was assumed to 
be p < 0.05. All statistical analyses were performed using 
JMP version 9.0.0 (SAS Institute Inc., USA).
Results
A total of 433 ports were implanted within five attempts 
without any complications including pneumothorax, hemo-
thorax, arterial puncture, or cardiovascular problems. The 
median indwelling period was 439.0 days (1–2824), the 
cumulative follow-up period was 251,538 catheter days, 
and the median event free period was 422.0 days (1–2824) 
(Table 1). The median indwelling periods were 499.0 
(1–2824) and 22.0 (1–2047) days in the CTx and non-CTx 
groups, respectively. In 87.2 % (41/47) of patients in the 
non-CTx group, the indwelling periods were <6 months. 
In contrast, 60.6 % (234/386) of patients in the CTx group 
could use UACVP for more than a year (Fig. 2). In the CTx 
group, 74 (19.2 %) patients received systemic CTx includ-
ing Bmab, a recombinant humanized monoclonal antibody 
directed against vascular endothelial growth factor, and 










Purpose of the implant
 Chemotherapy 386
 Other 47
Median duration of implant (range days) 439.0 (1–2824)
Total duration of implant (days) 251,538
Fig. 2  Indwelling periods of 
UACVPs according to the pur-
pose of implantation. The black 
and gray bars represent the 
number of patients in the CTx 
and non-CTx groups, respec-
tively. The median indwelling 
period was much shorter in the 
non-CTx group [22.0 (1–2047) 
days] compared to the CTx 
group [499.0 (1–2824) days]
No. Pts
within 6 month 6-12month 12-24month 24-36month 36-48month over 48month
non-CTx 41 3 1 1 0 1
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the cumulative follow-up period and the median indwell-
ing periods were 77,141 catheter days and 983.0 days 
(85–2810), respectively. The complication-free one-year 
port availability in all groups and the CTx group only was 
estimated at 86.0 and 87.3 %, respectively, whereas the 
overall one-year port availability in all groups and the CTx 
group only was estimated at 87.7 and 88.7 %, respectively 
(Fig. 3).
There was no UACVP-related mortality throughout 
this study. Of the 142 patients with an indwelling period 
<6 months, 47 out of 101 patients in the CTx group and 31 
out of 41 patients in the non-CTx group died due to dete-
rioration of their primary disease without any UACVP-
related complications. During the long-term follow-up, 
UACVP-related complications occurred in a total of 83 
patients (19.2 %) (Table 2). UACVP-related infections were 
evident in 43 patients (9.9 %, 0.17/1000 catheter days), and 
27 of those patients were diagnosed with catheter infection 
(6.2 %, 0.11/1000 catheter days). A blood culture test was 
positive for bacteria in seven patients (1.6 %, 0.03/1000 
catheter days) and for fungi in four patients (0.9 %, 
0.02/1000 catheter days), but was negative in 12 patients. 
Of these 12 negative patients, a culture test for the cathe-
ter was also negative in 10 patients, but had not been per-
formed in the remaining two patients. The UACVPs were 
removed in all patients suspected of catheter infection, who 
all recovered following the appropriate anti-bacterial and/
or anti-fungal treatment. Port pocket infection occurred 
in 16 patients (3.7 %, 0.064/1000 catheter days), and was 
treated by port removal in ten patients and by administra-
tion of broad-spectrum antibiotics in the other two patients. 
In 44 patients from the non-CTx group for fluid supplemen-
tation, catheter and port pocket infections were evident in 
3 (6.8 %) and 2 (4.5 %) patients, respectively. In contrast, 
Fig. 3  Complication-free 
1-year port availability (solid 
line) and the overall one-year 
port availability (dotted line) 
in all patients were evaluated 
by the Kaplan–Meier method. 
The complication-free 1-year 
port availability was estimated 
at 86.0 %, whereas the overall 
1-year port availability in the 
whole group was estimated at 
87.7 %
Table 2  CVP-related complications
Complications n Complication/1000 catheter days  
(complication rate; %)
Evulsion Treatment for the patients without evulsion
Antibiotic Anticoagulant Observation
Catheter infection 27 0.107 (6.2) 27 0 0 0
Port infection 16 0.064 (3.7) 14 2 0 0
Thrombosis 10 0.040 (2.3) 3 0 7 0
Obstruction 10 0.040 (2.3) 9 0 0 1
Catheter dislocation 9 0.036 (2.1) 9 0 0 0
Reserver leak 5 0.020 (1.2) 4 0 0 1
Skin complication (exposure) 4 0.016 (1.0) 4 0 0 0
Port rotation/flip 2 0.008 (0.5) 2 0 0 0
Total 83 72 2 7 2
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in the 389 patients from the CTx group, 24 (6.2 %) and 14 
(3.6 %) patients developed catheter and port pocket infec-
tions, respectively. There were no significant differences in 
infection rates (catheter and port pocket) between the non-
CTx and CTx groups (p = 0.80).
Of the ten patients with venous thrombosis (2.3 %, 
0.04/1000 catheter days), three complained of thrombo-
sis-related symptoms (swelling of the upper extremities, 
shoulder pain and respiratory distress), and systemic anti-
coagulant therapy was initiated promptly with a gradual 
amelioration of their symptoms. Asymptomatic thrombosis 
was detected in five patients on a regular computed tomog-
raphy examination performed every 3 or 4 months. In addi-
tion, concomitant, asymptomatic pulmonary embolism was 
confirmed radiographically in two of these five patients. 
All thrombotic patients underwent systemic anticoagulant 
therapy, and following the disappearance of the thrombi 
by the appropriate therapy, the UACVPs were removed in 
three patients who had no need for further chemotherapy. Of 
the 74 patients receiving Bmab-containing CTx, UACVP-
related complications occurred in 22 patients (28.9 %, 
0.29/1000 catheter days), including nine cases of UACVP-
related infections (seven catheter infection and two port 
pocket infection) (12.2 %, 0.12/1000 catheter days), three 
cases of venous thrombosis (4.1 %, 0.04/1000 catheter days) 
and four cases of catheter occlusion (5.4 %, 0.052/1000 
catheter days). Although the frequency of CVP-related com-
plications tended to be higher in the Bmab-containing CTx 
group compared to the Bmab-free group (p = 0.022), there 
were no significant differences in the incidences of venous 
thrombosis between the two groups (p = 0.4119).
Of the nine patients with catheter dislocations (2.1 %, 
0.036/1000 catheter days), two complained of chest or back 
pain at the initiation of routine CTx, whereas the remain-
ing seven patients were asymptomatic, and the catheter dis-
location was detected by a regular computed tomography 
examination. Port leakage was evident in five patients—the 
system was removed in four patients, and the other patient 
complained of mild swelling at the port pocket after each 
administration of CTx, possibly due to minimal leakage 
of the infusion. Since the patient’s performance status was 
unsatisfactory and there were no signs of infection, we did 
not replace it with a new system, and the cause of the port 
leakage remained unclear in this case. There were no cases 
of detectable fibrin sheath formation, catheter fracture or 
needle dislodgement. In a total of 118 patients including 47 
patients whose UACVPs were removed due to completion 
of chemotherapy, 31 (26.3 %) developed catheter infection, 
which was the main cause leading to port removal due to 
complications (Table 2).
With regard to the indwelling period at the onset of the 
UACVP-related complications (Fig. 4), port pocket infec-
tion, skin dehiscence and port leakage occurred within 
1 year after UACVP implantation. Although half of cath-
eter infection cases (13/27, 48 %) were evident within 
1 year after UACVP implantation, seven patients developed 
catheter infection >2 years after implantation. In contrast, 
venous thrombosis and catheter occlusion occurred regard-
less of the indwelling period.
Discussion
Although there are some arguments regarding the implanta-
tion site for CVPs, we have adopted UACVPs rather than 
chest CVPs because of the easier and safer access to the 
Fig. 4  Indwelling periods at 
the onset of UACVP-related 
complications. Among the 
74 patients with indwelling 
periods >3 years, 13 developed 
UACVP-related complica-
tions. UACVP-related infection 
tended to occur more frequently 
within one year after UACVP 
implantation, whereas venous 
thrombosis and catheter occlu-
sion occurred regardless of the 
indwelling period. The paren-
theses in the bottom line indi-
cate the number of patients with 
complications with UACVPs 
during the indicated period
0 12 24 36 48 60
Catheter Infection (27)
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central blood vessel, as supported by Marcy et al. [16]. 
In this study, the UACVPs were placed successfully in all 
patients without any implantation-related complications, 
including pneumothorax, hemothorax, arterial puncture, or 
cardiovascular problems. The rates of UACVP-related com-
plications including infection, thrombosis, dislocation and 
occlusion in this study were comparable to those of chest 
and forearm CVPs and other UACVPs reported previously 
[6, 7, 19–27] (Table 3). Consistent with a previous report 
describing US-guided implantation and the feasibility of 
UACVPs [18], we confirmed the safety of the implantation 
procedures and the long-term utility of UACVPs in a larger 
cohort of patients.
The incidence of CVP-related infection (catheter infec-
tion and port pocket infection) was low at 0.17/1000 cath-
eter days (10.0 %), although the routine administration 
of prophylactic antibiotics was not standard in this study. 
Since the proper usage of antibiotics in the management of 
CVPs has not been proposed yet, further prospective ran-
domized studies are warranted to determine whether pro-
phylactic antibiotics can effectively reduce the incidence 
of CVP-related infection. Regarding the management of 
CVP-related infections, the port system should be removed 
in cases of suspected bacteremia or confirmed bacteremia/
fungemia, along with the prompt commencement of proper 
antibacterial and/or antifungal treatment [28]. In cases of 
port pocket infection without any signs of bacteremia, port 
removal is not necessary for improvement of the infection, 
which can be treated by antibiotic therapy as in 2 out of 12 
cases of port pocket infection in this study.
With regard to the incidence of venous thrombosis, it 
was speculated that the longer intravascular catheter of an 
arm CVP system could increase the risk of venous throm-
bosis [29]. However, Marcy et al. argued that catheter-
related venous thrombosis was not associated with cath-
eter length [30, 31]. In accordance with their argument, 
an extensive analysis of forearm CVPs in a large cohort 
of patient’s [27] as well as in our study actually demon-
strated a lower incidence of venous thrombosis (Table 3). 
Regardless of the indwelling site of the CVPs, the prophy-
lactic administration of anticoagulants to prevent venous 
thrombosis is not recommended according to the Stand-
ards, Options and Recommendations (SOR) [32] and other 
guidelines [33]. However, it is well known that cancer 
patients are predisposed to thromboembolic diseases, and 
that chemotherapy can also raise the risk of thrombosis 
[34, 35]. In this study, asymptomatic venous thrombosis 
was detected in 7 out of the 10 patients, thereby preventing 
future life-threatening thrombosis. Therefore, one should 
pay attention to the development of asymptomatic throm-
bosis on regular computed tomography examinations in 
patients with UACVPs, regardless of the indwelling length 
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computed tomography in detecting venous thrombosis 
[36], we did not employ Doppler US in routine practice for 
the detection of venous thrombosis during the study period. 
Therefore, there was a possibility of underestimating the 
incidences of catheter-related thrombosis.
We examined whether the Bmab-containing CTx 
group had a tendency to develop venous thrombosis or 
not. According to a large pooled analysis of 6,055 cancer 
patients, the addition of Bmab to chemotherapy did not sta-
tistically significantly increase the risk of venous thrombo-
embolisms compared to chemotherapy alone [37]. In our 
study, no significant difference was observed in the inci-
dences of venous thrombosis between the Bmab-containing 
CTx group and the Bmab-free group (p = 0.4119). How-
ever the frequency of CVP–related complications tended 
to be higher in the Bmab-containing CTx group compared 
to the Bmab-free group (p = 0.022). Since the usage of 
CVPs was not evaluated in the pooled analysis, additional 
investigation is required to evaluate the effects of Bmab 
on the incidence of venous thrombosis and CVP-related 
complications.
The incidence of catheter dislocation in our study 
(2.1 %, 0.036/1000 catheter days) was compatible to that 
of previous reports [23–27]. Although we could not clarify 
the mechanisms responsible for the dislocation, extreme 
motion of the upper extremities might induce a migration 
of the catheter tip into the innominate or subclavian veins. 
Since a catheter dislocating into narrow veins can cause 
venous thrombosis, the catheter should be removed even 
when patients remain asymptomatic. Furthermore, if the 
patient complains of chest or back pain at the initiation of 
systemic administration or if catheter dysfunction occurs, 
the tip position of the catheter should be immediately eval-
uated by chest radiography or fluoroscopy with contrast 
medium. These precautions can prevent serious complica-
tions due to catheter dislocation. In ours study, no serious 
complications associated with catheter dislocation have 
occurred so far.
In our study, there were four cases of skin dehiscence 
and two cases of port chamber twist. In order to mini-
mize skin dehiscence, it seemed important to implant the 
UACVPs under the subcutaneous fat tissue, not just under 
the dermis. In one case of port chamber twist, the port was 
not fixed with any sutures. In the other case, the reason 
why the port was inverted in the small pocket remained 
unresolved. It would be desirable to fix the port with a few 
sutures in a pocket which just fits the size of that port.
UACVPs are well accepted, especially by female 
patients, in terms of more convenient CTx since they do 
not have to get undressed for the insertion or removal of a 
needle, thereby relieving the embarrassment of undressing. 
In addition, UACVPs can be easily covered with a short-
sleeved shirt. Since UACVPs are generally smaller than 
chest CVPs, one can experience some difficulty in insert-
ing the needle into a smaller puncture area of the UACVPs, 
especially in obese patients. The self-insertion of a needle 
is also sometimes difficult, since patients with UACVPs 
cannot hold the CVPs by themselves when they insert the 
needle. Therefore, UACVPs seem unsuitable for long-term 
total parenteral nutrition in patients with short-bowel syn-
drome and other gastrointestinal disorders, although the 
short-term usage of UACVPs can be useful for fluid sup-
plementation in advanced cancer patients as in the non-
CTx group.
In conclusion, UACVPs seem to be feasible especially 
for systemic CTx in terms of port availability, and could be 
one of the options for CVP implantation in patients with 
some difficulties in accessing their subclavian or internal 
jugular veins. However, since this is a retrospective study 
with some limitations, a randomized clinical trial compar-
ing the safety and utility between UACVPs and chest CVPs 
(including internal jugular vein access) is warranted.
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